IRIS
COVRE, ALESSIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.177
EU - Europa 2.890
AS - Asia 1.939
SA - Sud America 308
AF - Africa 104
OC - Oceania 10
Totale 9.428
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.106
RU - Federazione Russa 866
SG - Singapore 770
IT - Italia 638
CN - Cina 454
IE - Irlanda 434
VN - Vietnam 254
BR - Brasile 252
GB - Regno Unito 242
FR - Francia 191
HK - Hong Kong 161
SE - Svezia 135
DE - Germania 110
UA - Ucraina 77
ZA - Sudafrica 74
BD - Bangladesh 67
FI - Finlandia 67
IN - India 61
KR - Corea 47
CA - Canada 42
ES - Italia 40
NL - Olanda 22
PL - Polonia 18
IQ - Iraq 17
MX - Messico 16
TR - Turchia 14
AR - Argentina 13
AT - Austria 13
EC - Ecuador 13
JO - Giordania 10
AU - Australia 9
ID - Indonesia 9
JP - Giappone 9
KE - Kenya 9
AL - Albania 7
AZ - Azerbaigian 7
PH - Filippine 7
CL - Cile 6
CO - Colombia 6
UY - Uruguay 6
LT - Lituania 5
MA - Marocco 5
NP - Nepal 5
SA - Arabia Saudita 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
CR - Costa Rica 4
DZ - Algeria 4
IL - Israele 4
PY - Paraguay 4
MY - Malesia 3
NO - Norvegia 3
PA - Panama 3
PE - Perù 3
PK - Pakistan 3
RO - Romania 3
AM - Armenia 2
CH - Svizzera 2
EG - Egitto 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
IR - Iran 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
OM - Oman 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
UZ - Uzbekistan 2
BG - Bulgaria 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
JM - Giamaica 1
LB - Libano 1
MD - Moldavia 1
MR - Mauritania 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PT - Portogallo 1
SV - El Salvador 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 9.428
Salva come PNG Salva come JPEG
Città #
Dallas 739
Dublin 431
Singapore 428
Fairfield 407
Ashburn 301
San Jose 284
Moscow 248
Santa Clara 221
Woodbridge 183
Seattle 176
Cambridge 158
Hong Kong 157
Houston 156
Wilmington 154
Southend 150
Beijing 141
New York 100
Milan 88
Hefei 79
Los Angeles 74
Jacksonville 73
Princeton 73
Siena 72
The Dalles 72
Ho Chi Minh City 70
Johannesburg 70
Lauterbourg 68
Florence 67
Council Bluffs 51
Dong Ket 50
Helsinki 47
Rome 46
Ann Arbor 44
Seoul 44
Shanghai 44
Hanoi 43
San Mateo 38
San Diego 34
Chandler 30
Munich 27
Málaga 27
Dearborn 25
Stockholm 22
São Paulo 22
Redondo Beach 21
Borgo San Lorenzo 20
Buffalo 19
London 18
Lappeenranta 16
Orem 16
Chennai 15
Denver 15
Fremont 15
Montreal 15
Chicago 14
Toronto 14
Frankfurt am Main 13
Nuremberg 13
Palermo 13
San Francisco 13
Sesto Fiorentino 13
Warsaw 13
Haiphong 12
Modena 12
Phoenix 12
Atlanta 11
Poplar 11
Amsterdam 10
Empoli 10
Guangzhou 10
Manchester 10
Vienna 10
Bengaluru 9
Guayaquil 9
Naples 9
Perugia 9
Rio de Janeiro 9
Tokyo 9
Amman 8
Boardman 8
Da Nang 8
Piscataway 8
Portsmouth 8
Brooklyn 7
Mumbai 7
Barnet 6
Cascina 6
Charlotte 6
Düsseldorf 6
Hangzhou 6
Lucca 6
Mexico City 6
Montevideo 6
Ninh Bình 6
Orbetello 6
Redwood City 6
Sydney 6
Trieste 6
Asciano 5
Baku 5
Totale 6.414
Salva come PNG Salva come JPEG
Nome #
Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team 500
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 261
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 249
Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13–15, 2016 239
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 224
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 222
NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy 222
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 222
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours 211
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 208
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017 206
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 205
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 194
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 193
The biology of cancer testis antigens: putative function, regulation and therapeutic potential 189
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 188
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 185
A novel microRNA signature for the detection of melanoma by liquid biopsy 183
Epigenetically-regulated Tumor-Associated Antigens in melanoma 183
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 181
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 178
Immunotherapy targeting immune check-point(s) in brain metastases 175
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 174
5-AZA-2'-deoxycytidine in cancer immunotherapy: a mouse to man story 172
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 162
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 160
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 160
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 155
Whole genome methylation profiles as independent markers of survival in stage IIIc melanoma patients 155
Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications 155
Epigenetically‐Regulated Therapeutic Tumor‐Associated Antigens 151
Challenges in lung cancer therapy during the COVID-19 pandemic 148
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications 144
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma 140
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 139
Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status 136
Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients 135
COVID and Lung Cancer 133
Epigenetics meets immune checkpoints 130
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 130
Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. 127
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 120
Epigenetic mechanisms in cancer formation and progression 117
The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology 114
Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers? 112
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 111
Epigenetics of melanoma: implications for immune-based therapies. Immunotherapy, 5:1103-1116, 2013 111
Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 109
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide 106
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets 101
Immunotherapy of brain metastases: breaking a "dogma" 92
Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI) 92
Clonal heritability of CTA expression and promoter methylation patterns in melanoma cells: Bases for epigenetic therapy? 91
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy 89
The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma 87
Abstract 4841: DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy 83
Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy 81
Whole genome methylation profiles and survival of melanoma patients 76
Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer 70
Immunomodulatory activity of SGI-110, a secon generation hypometilating agent 62
Integrated multi-omics profiling reveals the role of the DNA methylation landscape in shaping biological heterogeneity and clinical behaviour of metastatic melanoma 61
Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome 60
Abstract 2632: A new paradigm for brain tumors treatment: Guadecitabine as a fundamental player to improve tumor immune response 59
Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study 22
Totale 9.650
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.989
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.989
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021105 0 0 0 0 0 0 0 0 0 0 0 105
2021/2022460 13 61 42 10 8 30 20 19 31 58 63 105
2022/2023517 50 36 103 49 11 94 17 29 41 29 41 17
2023/2024753 31 19 71 27 22 215 235 26 27 9 24 47
2024/20251.516 58 42 133 88 205 99 40 86 191 81 163 330
2025/20264.434 251 405 686 523 976 183 469 166 148 249 199 179
Totale 9.650